Navigation Links
GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
Date:9/25/2007

ST. JOSEPH, Mich., Sept. 25 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Bristol-Myers Squibb (NYSE: BMY) has licensed access to all major GeneGo products. Using the licensed GeneGo technology, research and development sites within Bristol-Myers Squibb will have the ability to start with chemical compound structures and/or genomics data to address questions from both chemistry and biology domains. Bristol-Myers Squibb can also access GeneGo tools to build their own canonical pathway maps using public, GeneGo, and proprietary data and have those maps included in statistical calculations and overlays. In addition, Bristol Myers Squibb researchers can leverage GeneGo products to overlay their own internal interaction data in the context of manually curated pathways for more elucidation.

"Bristol Myers Squibb is very important to GeneGo as they have excellent scientists who we have been collaborating with," said Julie Bryant, GeneGo's VP of Business Development. "We plan to continue this collaborative spirit over the next few years."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology
'/>"/>

SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , announced today ... approved the Company,s application to conduct a Phase 2 ... patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... Washington, USA (PRWEB) March 29, 2015 ... and the United States and plenary talks by four ... SPIE Optics + Optoelectronics next month in ... technical presentations in 17 conferences alongside a two-day exhibition. ... and photonics , the event will run 13-16 April ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015  FUJIFILM ... ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: Robert ... leading developer and manufacturer of fully functioning human cells ... the two companies have entered into a definitive agreement ... offer to be followed by a second step merger. ...
(Date:3/29/2015)... As a symbol of its commitment ... pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to announce ... Race Team for the 2015 race season. Success on ... a strong sense of precision and attention to detail. ... in the quality control testing laboratory. Sponsorship of the ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
... XI,AN, China, May 15 /Xinhua-PRNewswire-FirstCall/ -- Huifeng ... a leading,developer and producer of plant extracts ... nutraceutical and food production, today,announced that there ... as a result,of the Sichuan Earthquake., ...
... 15 Derma Sciences, Inc.,(OTC Bulletin Board: DSCI), a ... first quarter ended March 31, 2008. For the,quarter, sales ... sales,from the newly acquired First Aid Division. The Company ... higher than expected,integration costs associated with its First Aid ...
... 15 Debiopharm Group,(Debiopharm), a global ... medical conditions and particularly oncology, announced,the ... its long-term European,pharmaceutical partner, for the ... releasing hormone (GnRH) agonist analogue,effective in ...
Cached Biology Technology:Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities 2Derma Sciences Reports First Quarter 2008 Results 2Derma Sciences Reports First Quarter 2008 Results 3Derma Sciences Reports First Quarter 2008 Results 4Derma Sciences Reports First Quarter 2008 Results 5Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations 2
(Date:3/10/2015)...   Tute Genomics , pioneer in affordable, accurate ... sequencing company PrimBio Research Institute to be ... panel interpretation. PrimBio, a certified Life Technologies ... technologies to support the work of experts on the ... types of exome sequencing services: 1) Targeted Exome and ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biometrics Market Forecast ... The market for biometric authentication systems ... around 14% till 2020 The driving ... increasing security needs, government projects and constant development ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Personal Data Protection Company Launches New Product 2
... PASADENA, Calif.A California Institute of Technology (Caltech)-led ... first proof that a targeted nanoparticleused as an ... bloodstreamcan traffic into tumors, deliver double-stranded small interfering ... gene using a mechanism known as RNA interference ...
... A potential new energy source so controversial that people once ... by the mainstream scientific community. That,s the conclusion of the ... topic "cold fusion" being held here for the ... National Meeting of the American Chemical Society (ACS). "Years ...
... , , Michael M. Graham, Ph.D., M.D., president, ... chair, SNM Medical Isotope Task Force, Jeffrey P. Norenberg, ... member, SNM Medical Isotope Task Force, WHEN:,Immediately ... over a two-week period when cancer, heart and brain ...
Cached Biology News:Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 2Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 3Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 4'Cold fusion' moves closer to mainstream acceptance 2'Cold fusion' moves closer to mainstream acceptance 3'Cold fusion' moves closer to mainstream acceptance 4
... the 9, 10, 12, and 13 positions. It ... for the quantification of 13(S)-HODE by GC- or ... linoleic acid with plant and mammalian lipoxygenases. It ... tumor cells to the endothelium at concentrations around ...
... and TriEx Insect Cell Medium are recommended ... This cell/medium combination has been selected based ... protein expression levels observed specifically with baculoviruses ... that our Ready-Plaque Sf9 Cells and BacVector ...
...
...
Biology Products: